These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 27131066)
1. An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core. Song Z; Xia Z; Ji Y; Xing L; Gao Y; Ai J; Geng M; Zhang A Eur J Med Chem; 2016 Aug; 118():244-9. PubMed ID: 27131066 [TBL] [Abstract][Full Text] [Related]
2. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study. Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749 [TBL] [Abstract][Full Text] [Related]
3. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866 [TBL] [Abstract][Full Text] [Related]
4. Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core. Han M; Wang C; Ji Y; Song Z; Xing L; Su Y; Wang X; Zhang A; Ai J; Geng M Bioorg Med Chem Lett; 2016 Nov; 26(22):5399-5402. PubMed ID: 27769623 [TBL] [Abstract][Full Text] [Related]
5. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307 [TBL] [Abstract][Full Text] [Related]
6. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P J Pharmacol Exp Ther; 2014 Oct; 351(1):67-76. PubMed ID: 25073473 [TBL] [Abstract][Full Text] [Related]
7. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728 [TBL] [Abstract][Full Text] [Related]
8. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase. Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428 [TBL] [Abstract][Full Text] [Related]
10. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins. Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells. Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637 [TBL] [Abstract][Full Text] [Related]
12. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674 [TBL] [Abstract][Full Text] [Related]
13. Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer. Kang CH; Kim EY; Kim HR; Lee CO; Lee HK; Jeong HG; Choi SU; Yun CS; Hwang JY; Lee JY; Son YH; Ahn S; Lee BH; Jung H; Park CH Cancer Lett; 2016 May; 374(2):272-8. PubMed ID: 26923554 [TBL] [Abstract][Full Text] [Related]
14. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer. Meng S; Wu H; Wang J; Qiu Q Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045 [TBL] [Abstract][Full Text] [Related]
15. Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases. Song Z; Yang Y; Liu Z; Peng X; Guo J; Yang X; Wu K; Ai J; Ding J; Geng M; Zhang A J Med Chem; 2015 Jan; 58(1):197-211. PubMed ID: 24785465 [TBL] [Abstract][Full Text] [Related]
16. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559 [TBL] [Abstract][Full Text] [Related]
17. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Lovly CM; Heuckmann JM; de Stanchina E; Chen H; Thomas RK; Liang C; Pao W Cancer Res; 2011 Jul; 71(14):4920-31. PubMed ID: 21613408 [TBL] [Abstract][Full Text] [Related]
18. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618 [TBL] [Abstract][Full Text] [Related]
19. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Rodig SJ; Shapiro GI Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]